Administration of TGF-b Resistant LMP2A-Specific Cytotoxic T-Lymphocytes to Patients With Relapsed EBV-Positive Lymphoma

Trial Profile

Administration of TGF-b Resistant LMP2A-Specific Cytotoxic T-Lymphocytes to Patients With Relapsed EBV-Positive Lymphoma

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 05 Sep 2017

At a glance

  • Drugs Epstein-Barr virus-specific cytotoxic T lymphocytes (Primary)
  • Indications Hodgkin's disease; Non-Hodgkin's lymphoma
  • Focus Adverse reactions
  • Acronyms TGF-beta
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 16 Sep 2016 Planned primary completion date changed from 1 Aug 2016 to 1 Aug 2017.
    • 16 Sep 2016 Planned primary completion date changed from 1 Aug 2016 to 1 Aug 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top